ArticleEuropean journal of endocrinology2022
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.
Article in European journal of endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- The usefulness of cannulated prolactin test in mild hyperprolactinemia: case series and systematic review of the literature.Pituitary · 2026Pooled it
- Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire.International journal of impotence research · 2024Pooled it
- Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases.Nature reviews. Endocrinology · 2024Guideline
- Italian Guidelines for the Management of Prolactinomas.Endocrine, metabolic & immune disorders drug targets · 2023Guideline
- Predictors of prolonged hypogonadism in men with prolactinomas despite biochemical remission: the role of baseline luteinizing hormone.Journal of endocrinological investigation · 2026Article
- Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).Chinese neurosurgical journal · 2026Review
- Article
- Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia.Pituitary · 2026Article
- Pregnancy and delivery after surgical remission in women with prolactinomas desiring pregnancy: Refining surgical indications.Pituitary · 2026Article
- Endoscopic surgery for noninvasive prolactinomas: A large multicenter, single-arm, retrospective study (PRLomaSaR).Endocrine · 2026Article
- Prolactinomas treated with dopaminergic agonists: behavior in different moments of life.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026Article
- Analysis of senescence in pituitary tumors from different lineages and the potential role of senolytic drugs as targeted therapies.Frontiers in endocrinology · 2026Article
- Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists.Endocrine · 2025Article
- Prolactin secreting pituitary neuroendocrine tumors treated by dopamine agonists: predictors of response.Frontiers in endocrinology · 2025Article
- Modern approach to bone comorbidity in prolactinoma.Pituitary · 2024Review
- Identification of Prolactinoma in Pituitary Neuroendocrine Tumors Using Radiomics Analysis Based on Multiparameter MRI.Journal of imaging informatics in medicine · 2024Article
- Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma.Acta neurochirurgica · 2024Article
- A Non-Secreting Pituitary Adenoma That Changed to a Prolactinoma.Clinics and practice · 2024Article
- Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight.BMC endocrine disorders · 2024Article
- Prediction of adrenal insufficiency after pituitary surgery: a retrospective study using beckman access cortisol assay.Pituitary · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 17 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different clinical settings and always require an individually tailored approach. This is the reason why a panel of Italian neuroendocrine experts was charged with the task to provide indications for the diagnostic and therapeutic approaches that can be easily applied in different contexts. The document provides 15 recommendations for diagnosis and 54 recommendations for treatment, issued according to the GRADE system. The level of agreement among panel members was formally evaluated by RAND-UCLA methodology. In the last century, prolactinomas represented the paradigm of pituitary tumors for which the development of highly effective drugs obtained the best results, allowing to avoid neurosurgery in most cases. The impressive improvement of neurosurgical endoscopic techniques allows a far better definition of the tumoral tissue during surgery and the remission of endocrine symptoms in many patients with pituitary tumors. Consequently, this refinement of neurosurgery is changing the therapeutic strategy in prolactinomas, allowing the definitive cure of some patients with permanent discontinuation of medical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.